
|Articles|June 1, 2002
Molecule engineered to target neovascularization in AMD
A genetically engineered molecule designed to kill cancers by destroying their rapidly growing blood vessels offers a new line of attack against age-related macular degeneration (AMD) and other retinal conditions, said Alan Garen, PhD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Spotlight on women's health: Understanding thyroid eye disease
2
FDA extends Aldeyra's reproxalap PDUFA after requesting additional clinical study report
3
NCX 470 advances toward US, China NDA submissions for NCX 470
4
Unmet Needs in Dry Eye Disease
5








































